Basel (Switzerland) and Mannheim (Germany), September 28, 2018 – VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that the Company will participate in several upcoming events in the fourth quarter of 2018.
Sachs 18th Annual Biotech in Europe Forum
October 4-5, 2018
Heinz Lubenau, PhD, Chief Operating Officer of VAXIMM, will give a corporate presentation on October 4th at 3:30 PM CET. The Company will also host one-on-one meetings at this event. To request a meeting with VAXIMM, please sign up through the event’s meeting system. The Biotech in Europe Forum organized by Sachs Associates attracts approximately 650 delegates in investing and partnering in the biotech and life science industry. More information on the event can be found here.
13th Meeting of the European Association of Neuro-Oncology (EANO)
October 10-14, 2018
Data will be presented on VAXIMM’s lead oral T-cell immunotherapy program, VXM01, in a poster (#P01.031) entitled, “VXM01 phase I study in patients with progressive glioblastoma – final results.” The poster will be presented during Poster Session I, Glioma – Clinical Aspects, on October 12th, 5:00-6:00 PM CET. More information on the event can be found here.
November 5-7, 2018
VAXIMM will give a corporate presentation and host one-on-one meetings at this event. To request a meeting with VAXIMM, please sign up through the event’s partneringONE meeting system. For more information on the event, please click here.
23rd Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO)
November 15-18, 2018
New Orleans, LA, USA
Data will be presented on VXM01 in a poster (#ATIM-35) entitled, “VXM01 phase I study in patients with progressive glioblastoma – final results.” The poster will be presented on November 16th, 7:30-9:30 PM CT. For more information about the meeting, please click here.
VAXIMM is a privately held, Swiss/German biotech company that is developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM’s product platform is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients’ cytotoxic T-cells to target specific structures of the tumor. The Company has a pipeline of complementary development candidates targeting different tumor structures. Lead product candidate, oral VXM01, activates killer cells targeting tumor-specific vasculature and certain immune-suppressive cells, thereby increasing immune cell infiltration in solid tumors. VXM01 is currently in clinical development for several tumor types, including pancreatic, colorectal and brain cancer. VAXIMM has a collaboration agreement with China Medical System Holdings (CMS), granting CMS full rights in China and other Asian countries (excluding Japan) to VAXIMM’s existing programs. CMS has made an equity investment in VAXIMM; the Company’s other investors include BB Biotech Ventures, M Ventures, Sunstone Capital and BioMed Partners. VAXIMM AG is headquartered in Basel, Switzerland. Its wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the Company’s development activities. For more information, please see www.vaximm.com.
Dr. Heinz Lubenau
Tel.: +49 621 8359 687 0
MC Services AG
Katja Arnold, Laurie Doyle
Tel: +49 89 210228 0